Myeloid Leukemia Nursing Case Study

Myeloid Leukemia Nursing Case Study

My articles are on Myeloid Leukemia

1. Write a proposal about what the research journal is about (the three articles).minimum of 150 words.

2. Discuss emerging technologies in healthcare and their application to providing safe and effective care.

Explain a position on the advancement of healthcare informatics and technology in healthcare 250 words/APA style/ References

Review article

The molecular biology of chronic myeloid leukemia Michael W. N. Deininger, John M. Goldman, and Junia V. Melo

Chronic myeloid leukemia (CML) is probably the most extensively studied human malignancy. The discovery of the Philadelphia (Ph) chromosome in 19601 as the first consistent chromosomal abnormal- ity associated with a specific type of leukemia was a breakthrough in cancer biology. It took 13 years before it was appreciated that the Ph chromosome is the result of a t(9;22) reciprocal chromosomal translocation2 and another 10 years before the translocation was shown to involve theABL proto-oncogene normally on chromo- some 93 and a previously unknown gene on chromosome 22, later termedBCR for breakpoint cluster region.4 The deregulated Abl tyrosine kinase activity was then defined as the pathogenetic principle,5 and the first animal models were developed.6 The end of the millennium sees all this knowledge transferred from the bench to the bedside with the arrival of Abl-specific tyrosine kinase inhibitors that selectively inhibit the growth ofBCR-ABL–positive cells in vitro7,8 and in vivo.9


In this review we will try to summarize what is currently known about the molecular biology of CML. Because several aspects of CML pathogenesis may be attributable to the altered function of the 2 genes involved in the Ph translocation, we will also address the physiological roles ofBCRandABL. We concede that a review of this nature can never be totally comprehensive without losing clarity, and we therefore apologize to any authors whose work we have not cited. Myeloid Leukemia Nursing Case Study

The physiologic function of the translocation partners

The ABL gene is the human homologue of the v-abl oncogene carried by the Abelson murine leukemia virus (A-MuLV),10 and it encodes a nonreceptor tyrosine kinase.11 Human Abl is a ubiqui- tously expressed 145-kd protein with 2 isoforms arising from alternative splicing of the first exon.11 Several structural domains can be defined within the protein (Figure 1). Three SRC homology domains (SH1-SH3) are located toward the NH2 terminus. The SH1 domain carries the tyrosine kinase function, whereas the SH2 and SH3 domains allow for interaction with other proteins.12

Proline-rich sequences in the center of the molecule can, in turn, interact with SH3 domains of other proteins, such as Crk.13 Toward the 39 end, nuclear localization signals14 and the DNA-binding15

and actin-binding motifs16 are found. Several fairly diverse functions have been attributed to Abl, and

the emerging picture is complex. Thus, the normal Abl protein is involved in the regulation of the cell cycle,17,18 in the cellular

response to genotoxic stress,19 and in the transmission of informa- tion about the cellular environment through integrin signaling.20

(For a comprehensive review of Abl function, see Van Etten21). Overall, it appears that the Abl protein serves a complex role as a cellular module that integrates signals from various extracellular and intracellular sources and that influences decisions in regard to cell cycle and apoptosis. It must be stressed, however, that many of the data are based solely on in vitro studies in fibroblasts, not hematopoietic cells, and are still controversial. Unfortunately, the generation ofABL knockout mice failed to resolve most of the outstanding issues.22,23

The 160-kd Bcr protein, like Abl, is ubiquitously expressed.11

Several structural motifs can be delineated (Figure 2). The first N-terminal exon encodes a serine–threonine kinase. The only substrates of this kinase identified so far are Bap-1, a member of the 14-3-3 family of proteins,24 and possibly Bcr itself.11 A coiled–coil domain at the N-terminus of Bcr allows dimer formation in vivo.25

The center of the molecule contains a region withdbl-like and pleckstrin-homology (PH) domains that stimulate the exchange of guanidine triphosphate (GTP) for guanidine diphosphate (GDP) on Rho guanidine exchange factors,26 which in turn may activate transcription factors such as NF-kB.27 The C-terminus has GTPase activity for Rac,28 a small GTPase of the Ras superfamily that regulates actin polymerization and the activity of an NADPH oxidase in phagocytic cells.29 In addition, Bcr can be phosphory- lated on several tyrosine residues,30 especially tyrosine 177, which binds Grb-2, an important adapter molecule involved in the activation of the Ras pathway.31 Interestingly, Abl has been shown to phosphorylate Bcr in COS1 cells, resulting in a reduction of Bcr kinase activity.31,32Although these data argue for a role of Bcr in signal transduction, their true biologic relevance remains to be determined. The fact thatBCRknockout mice are viable and the fact that an increased oxidative burst in neutrophils is thus far the only recognized defect33 probably reflect the redundancy of signaling pathways. If there is a role for Bcr in the pathogenesis of Ph-positive leukemias, it is not clearly discernible because the incidence and biology of P190BCR-ABL-induced leukemia are the same inBCR2/2 mice as they are in wild-type mice.34 Myeloid Leukemia Nursing Case Study

Molecular anatomy of the BCR-ABL translocation

The breakpoints within theABL gene at 9q34 can occur anywhere over a large (greater than 300 kb) area at its 59 end, either upstream

From the Department of Hematology/Oncology, University of Leipzig, Germany; and the Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom.

Submitted November 16, 1999; accepted July 12, 2000.

Supported by grants from Leukaemia Research Fund (UK) and the Dr Ernst und Anita Bauer Stiftung (Germany).

Reprints: Michael W. N. Deininger, Department of Hematology/Oncology,

University of Leipzig, Johannisallee 32, Leipzig 04103, Germany; e-mail: [email protected].

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked ‘‘advertisement’’ in accordance with 18 U.S.C. section 1734.

© 2000 by The American Society of Hematology

3343BLOOD, 15 NOVEMBER 2000 z VOLUME 96, NUMBER 10

D ow

nloaded from by guest on 15 M

ay 2020

of the first alternative exon Ib, downstream of the second alterna- tive exon Ia, or, more frequently, between the two35 (Figure 3). Regardless of the exact location of the breakpoint, splicing of the primary hybrid transcript yields an mRNA molecule in whichBCR sequences are fused toABL exon a2. In contrast toABL, break- points withinBCR localize to 1 of 3 so-called breakpoint cluster regions (bcr). In most patients with CML and in approximately one third of patients with Ph-positive acute lymphoblastic leukemia (ALL), the break occurs within a 5.8-kb area spanningBCRexons 12-16 (originally referred to as exons b1-b5), defined as the major breakpoint cluster region (M-bcr). Because of alternative splicing, fusion transcripts with either b2a2 or b3a2 junctions can be formed. A 210-kd chimeric protein (P210BCR-ABL) is derived from this mRNA. In the remaining patients with ALL and rarely in patients with CML, characterized clinically by prominent monocytosis,36,37

the breakpoints are further upstream in the 54.4-kb region between the alternativeBCRexons e29 and e2, termed the minor breakpoint cluster region (m-bcr). The resultant e1a2 mRNA is translated into a 190-kd protein (P190BCR-ABL). Recently, a third breakpoint cluster region (m-bcr) was identified downstream of exon 19, giving rise to a 230-kd fusion protein (P230BCR-ABL) associated with the rare Ph-positive chronic neutrophilic leukemia,38 though not in all cases.39 If sensitive techniques such as nested reverse transcription– polymerase chain reaction are used, transcripts with the e1a2 fusion are detectable in many patients with classical P210BCR-ABLCML.40 Myeloid Leukemia Nursing Case Study

The low level of expression of these P190-type transcripts com- pared to P210 indicates that they are most likely the result of alternative splicing of the primary mRNA. Occasional cases with other junctions, such as b2a3, b3a3, e1a3, e6a2,41 or e2a2,42 have been reported in patients with ALL and CML. These “experiments of nature” provide important information as to the function of the

various parts ofBCR and ABL in the oncogenic fusion protein. Interestingly,ABLexon 1, even if retained in the genomic fusion, is never part of the chimeric mRNA. Thus, it must be spliced out during processing of the primary mRNA; the mechanism underly- ing this apparent peculiarity is unknown. Based on the observation that the Abl part in the chimeric protein is almost invariably constant while the Bcr portion varies greatly, one may deduce that Abl is likely to carry the transforming principle whereas the different sizes of the Bcr sequence may dictate the phenotype of the disease. In support of this notion, rare cases of ALL express a TEL-ABL fusion gene,43,44 indicating that theBCRmoiety can in principle be replaced by other sequences and still cause leukemia. Interestingly, a fusion betweenTEL(ETV6)and theABL-related geneARG has recently been described in a patient with AML.45

Although all 3 major Bcr-Abl fusion proteins induce a CML-like disease in mice, they differ in their ability to induce lymphoid leukemia,46 and, in contrast to P190 and P210, transformation to growth factor independence by P230BCR-ABL is incomplete,47 which is consistent with the relatively benign clinical course of P230- positive chronic neutrophilic leukemia.38 Myeloid Leukemia Nursing Case Study

One of the most intriguing questions relates to the events responsible for the chromosomal translocation in the first place. From epidemiologic studies it is well known that exposure to ionizing radiation (IR) is a risk factor for CML.48,49 Moreover, BCR-ABLfusion transcripts can be induced in hematopoietic cells by exposure to IR in vitro50; such IR-induced translocations may not be random events but may depend on the cellular background and on the particular genes involved. Two recent reports showed that the physical distance between theBCRand theABL genes in human lymphocytes51 and CD341 cells52 is shorter than might be expected by chance; such physical proximity could favor transloca- tion events involving the 2 genes. However, the presence of the BCR-ABL translocation in a hematopoietic cell is not in itself sufficient to cause leukemia becauseBCR-ABLfusion transcripts of M-bcr and m-bcr type are detectable at low frequency in the blood of many healthy individuals.53,54 It is unclear why Ph-positive leukemia develops in a tiny minority of these persons. It may be that the translocation occurs in cells committed to terminal differentiation that are thus eliminated or that an immune response suppresses or eliminates Bcr-Abl–expressing cells. Indirect evi- dence that such a mechanism may be relevant comes from the observation that certain HLA types protect against CML.55Another possibility is thatBCR-ABLis not the only genetic lesion required to induce chronic-phase CML. Indeed, a skewed pattern of G-6PD

Figure 1. Structure of the Abl protein. Type Ia isoform is slightly shorter than type Ib, which contains a myristoylation (myr) site for attachment to the plasma mem- brane. Note the 3 SRC-homology (SH) domains situated toward the NH2 terminus. Y393 is the major site of autophosphorylation within the kinase domain, and phenylalanine 401 (F401) is highly conserved in PTKs containing SH3 domains. The middle of each protein is dominated by proline-rich regions (PxxP) capable of binding to SH3 domains, and it harbors 1 of 3 nuclear localization signals (NLS). The carboxy terminus contains DNA as well as G- and F-actin–binding domains. Phosphorylation sites by Atm, cdc2, and PKC are shown. The arrowhead indicates the position of the breakpoint in the Bcr-Abl fusion protein.

Figure 2. Structure of the Bcr protein. Note the dimerization domain (DD) and the 2 cyclic adenosine monophosphate kinase homologous domains at the N terminus. Y177 is the autophosphorylation site crucial for binding to Grb-2. The center of the molecule contains a region homologous to Rho guanidine nucleotide exchange factors (Rho-GEF) as well as dbl-like and pleckstrin homology (PH) domains. Toward the C-terminus a putative site for calcium-dependent lipid binding (CaLB) and a domain with activating function for Rac-GTPase (Rac-GAP) are found. Arrowheads indicate the position of the breakpoints in the BCR-ABL fusion proteins.

Figure 3. Locations of the breakpoints in the ABL and BCR genes and structure of the chimeric mRNAs derived from the various breaks.


D ow

nloaded from by guest on 15 M

ay 2020

isoenzymes has been detected in Ph-negative Epstein-Barr virus- transformed B-cell lines derived from patients with CML, suggest- ing that a Ph-negative pathologic state may precede the emergence of the Ph chromosome.56 Myeloid Leukemia Nursing Case Study

Mechanisms of BCR-ABL –mediated malignant transformation

Essential features of the Bcr-Abl protein

Mutational analysis identified several features in the chimeric protein that are essential for cellular transformation (Figure 4). In Abl they include the SH1, SH2, and actin-binding domains (Figure 1), and in Bcr they include a coiled–coil motif contained in amino acids 1-63,25 the tyrosine at position 177,57 and phosphoserine– threonine-rich sequences between amino acids 192-242 and 298- 41358 (Figure 2). It is, however, important to note that essential features depend on the experimental system. For example, SH2 deletion mutants of Bcr-Abl are defective for fibroblast transforma- tion,59 but they retain the capacity to transform cell lines to factor independence and are leukemogenic in animals.60

Deregulation of the Abl tyrosine kinase

Abl tyrosine kinase activity is tightly regulated under physi- ologic conditions. The SH3 domain appears to play a critical role in this inhibitory process because its deletion14 or positional alteration61 activates the kinase; it is replaced by viralgag sequences in v-abl.62 Both cis- and trans-acting mechanisms have been proposed to mediate the repression of the kinase. Several proteins have been identified that bind to the SH3 domain.63-65 Abi-1 and Abi-2 (Abl interactor proteins 1 and 2) activate the inhibitory function of the SH3 domain; even more interesting, activated Abl proteins promote the proteasome- mediated degradation of Abi-166 and Abi-2. Another candidate inhibitor of Abl is Pag/Msp23. On exposure of cells to oxidative stress such as ionizing radiation, this small protein is oxidized and dissociates from Abl, whose kinase is in turn activated.67

These results are in line with previous observations that highly purified Abl protein is kinase-active,61 suggesting that its constitutive inhibition derives from a trans-acting mechanism. Alternatively, the SH3 domain may bind internally to the proline-rich region in the center of the Abl protein, causing a conformational change that inhibits interaction with sub- strates.68 Furthermore, a mutation of Phe401 to Val (within the

kinase domain) leads to the transformation of rodent fibroblasts. Because this residue is highly conserved in tyrosine kinases with N-terminal SH3 domains, it may bind internally to the SH3 domain.69 It is conceivable that the fusion of Bcr sequences 59 of the Abl SH3 domain abrogates the physiologic suppression of the kinase. This might be the consequence of homodimer formation; indeed, the N-terminal dimerization domain is an essential feature of the Bcr-Abl protein but can be functionally replaced by other sequences that allow for dimer formation, such as the N-terminus of theTEL (ETV-6) transcription factor in the TEL-ABL fusion associated with the t(9;12).43,70 It is possible that deregulated tyrosine kinase activity is a unifying feature of chronic myeloproliferative disorders. Several other reciprocal translocations have been cloned from patients with chronic BCR-ABL–negative myeloproliferative disorders. Re- markably, most of these turn out to involve tyrosine kinases such as fibroblast growth factor receptor 171 and platelet-derived growth factorb receptor (PDGFbR).72

A host of substrates can be tyrosine phosphorylated byBcr-Abl (Table 1). Most important, because of autophosphorylation, there is a marked increase of phosphotyrosine onBcr-Abl itself, which creates binding sites for the SH2 domains of other proteins. Generally, substrates ofBcr-Abl can be grouped according to their physiologic role into adapter molecules (such as Crkl and p62DOK), proteins associated with the organization of the cytoskeleton and the cell membrane (such as paxillin and talin), and proteins with catalytic function (such as the nonreceptor tyrosine kinase Fes or the phosphatase Syp). It is important to note that the choice of substrates depends on the cellular context. For example, Crkl is the major tyrosine-phosphorylated protein in CML neutrophils,73

whereas phosphorylated p62DOK is predominantly found in early progenitor cells.74 Myeloid Leukemia Nursing Case Study

Tyrosine phosphatases counterbalance and regulate the effects of tyrosine kinases under physiologic conditions, keeping cellular phosphotyrosine levels low. Two tyrosine phosphatases, Syp83 and PTP1B,84 have been shown to form complexes with Bcr-Abl, and both appear to dephosphorylate Bcr-Abl. Interestingly, PTP1B levels increase in a kinase-dependent manner, suggesting that the cell attempts to limit the impact of Bcr-Abl tyrosine kinase activity. At least in fibroblasts, transformation by Bcr-Abl is impaired by the overexpression of PTP1B.85 Interestingly, we recently observed the up-regulation of receptor protein tyrosine phosphatasek (RPTP-k) with the inhibition of Bcr-Abl in BV173 cells treated with the

Figure 4. Signaling pathways activated in BCR-ABL –positive cells. Note that this is a simplified diagram and that many more associations between Bcr-Abl and signaling proteins have been reported.

Table 1. Substrates of BCR-ABL

Protein Function Reference

P62DOK Adapter 74

Crkl Adapter 73

Crk Adapter 13

Shc Adapter 75

Talin Cytoskeleton/cell membrane 76

Paxillin Cytoskeleton/cell membrane 77

Fak Cytoskeleton/cell membrane 78

Fes Myeloid differentiation 79

Ras-GAP Ras-GTPase 80

GAP-associated proteins Ras activation? 214

PLCg Phospholipase 80

PI3 kinase (p85 subunit) Serine kinase 127

Syp Cytoplasmic phosphatase 83

Bap-1 14-3-3 protein 24

Cbl Unknown 81

Vav Hematopoietic differentiation 82


D ow

nloaded from by guest on 15 M

ay 2020

tyrosine kinase inhibitor STI571,86 which suggests that the oppo- site effect may also occur. Thus, though the pivotal role of Bcr-Abl tyrosine kinase activity is clearly established, much remains to be learned about the significance of tyrosine phosphatases in the transformation process.

Activated signaling pathways and biologic properties of BCR-ABL–positive cells

Three major mechanisms have been implicated in the malignant transformation byBcr-Abl, namely altered adhesion to stroma cells and extracellular matrix,87 constitutively active mitogenic signal- ing88 and reduced apoptosis89 (Figure 5). A fourth possible mechanism is the recently described proteasome-mediated degrada- tion of Abl inhibitory proteins.66 Myeloid Leukemia Nursing Case Study

Altered adhesion properties

CML progenitor cells exhibit decreased adhesion to bone marrow stroma cells and extracellular matrix.87,90 In this sce- nario, adhesion to stroma negatively regulates cell proliferation, and CML cells escape this regulation by virtue of their perturbed adhesion properties. Interferon-a (IFN-a), an active therapeutic agent in CML, appears to reverse the adhesion defect.91 Recent data suggest an important role forb-integrins in the interaction between stroma and progenitor cells. CML cells express an adhesion-inhibitory variant ofb1 integrin that is not found in normal progenitors.92 On binding to their receptors, integrins are capable of initiating normal signal transduction from outside to inside93; it is thus conceivable that the transfer of signals that normally inhibit proliferation is impaired in CML cells. Because Abl has been implicated in the intracellular transduction of such signals, this process may be further disturbed by the presence of a large pool of Bcr-Abl protein in the cytoplasm. Furthermore, Crkl, one of the most prominent tyrosine-phosphorylated pro- teins in Bcr-Abl–transformed cells,73 is involved in the regula- tion of cellular motility94 and in integrin-mediated cell adhe- sion95 by association with other focal adhesion proteins such as paxillin, the focal adhesion kinase Fak, p130Cas,96 and Hef1.97

We recently demonstrated that Bcr-Abl tyrosine kinase up- regulates the expression ofa6 integrin mRNA,86 which points to transcriptional activation as yet another possible mechanism by which Bcr-Abl may have an impact on integrin signaling. Thus, though there is sound evidence that Bcr-Abl influences integrin function, it is more difficult to determine the precise nature of the biologic consequences, and, at least in certain cellular systems, integrin function appears to be enhanced rather than reduced by Bcr-Abl.98

Activation of mitogenic signaling

Ras and the MAP kinase pathways.Several links between Bcr-Abl and Ras have been defined. Autophosphorylation of tyrosine 177 provides a docking site for the adapter molecule Grb-2.57 Grb-2, after binding to the Sos protein, stabilizes Ras in its active GTP-bound form. Two other adapter molecules, Shc and Crkl, can also activate Ras. Both are substrates of Bcr-Abl73,99and bind Bcr-Abl through their SH2 (Shc) or SH3 (Crkl) domains. The relevance of Ras activation by Crkl is, however, questionable because it appears to be restricted to fibroblasts.100Moreover, direct binding of Crkl to Bcr-Abl is not required for the transformation of myeloid cells.101 Circumstantial evidence that Ras activation is important for the pathogenesis of Ph-positive leukemias comes from the observation that activating mutations are uncommon, even in the blastic phase of the disease,102 unlike in most other tumors. This implies that the Ras pathway is constitutively active, and no further activating mutations are required. There is still dispute as to which mitogen-activated protein (MAP) kinase pathway is down- stream of Ras in Ph-positive cells. Stimulation of cytokine receptors such as IL-3 leads to the activation of Ras and the subsequent recruitment of the serine–threonine kinase Raf to the cell membrane.103 Raf initiates a signaling cascade through the serine–threonine kinases Mek1/Mek2 and Erk, which ultimately leads to the activation of gene transcription.104Although some data indicate that this pathway may be activated only in v-abl– but not in BCR-ABL–transformed cells,105 this view has recently been chal- lenged.106 Moreover, activation of the Jnk/Sapk pathway by Bcr-Abl has been demonstrated and is required for malignant transformation107; thus, signaling from Ras may be relayed through the GTP–GDP exchange factor Rac108 to Gckr (germinal center kinase related)109and further down to Jnk/Sapk (Figure 6). There is also some evidence that p38, the third pillar of the MAP kinase pathway, is also activated in BCR-ABL–transformed cells, and there are other pathways with mitogenic potential. In any case, the signal is eventually transduced to the transcriptional machinery of the cell. Myeloid Leukemia Nursing Case Study

It is also possible that Bcr-Abl uses growth factor pathways in a more direct way. For example, association with thebc subunit of the IL-3 receptor110 and the Kit receptor111 has been observed. Interestingly, the pattern of tyrosine-phosphorylated proteins seenFigure 5. Mechanisms implicated in the pathogenesis of CML.

Figure 6. Signaling pathways with mitogenic potential in BCR-ABL –trans- formed cells. The activation of individual paths depends on the cell type, but the MAP kinase system appears to play a central role. Activation of p38 has been demonstrated only in v-abl–transformed cells, whereas data for BCR-ABL– expressing cells are missing.


D ow

nloaded from by guest on 15 M

ay 2020

in normal progenitor cells after stimulation with Kit ligand is similar to the pattern seen in CML progenitor cells.112 Dok-1 (p62DOK), one of the most prominent phosphoproteins in this setting, forms complexes with Crkl, RasGAP, and Bcr-Abl. In fact, there may be a whole family of related proteins with similar functions—for example, the recently described Dok-2 (p56DOK2).113

Somewhat surprisingly, p62DOK is essential for transformation of Rat-1 fibroblasts but not for growth-factor independence of my- eloid cells114; thus, its true role remains to be defined.

Jak-Stat pathway.The first evidence for involvement of the Jak- Stat pathway came from studies in v-abl–transformed B cells.62 Consti- tutive phosphorylation of Stat transcription factors (Stat1 and Stat5) has since been reported in several BCR-ABL–positive cell lines115 and in primary CML cells,116 and Stat5 activation appears to contribute to malignant transformation.117Although Stat5 has pleiotropic physiologic functions,118 its effect in BCR-ABL–transformed cells appears to be primarily anti-apoptotic and involves transcriptional activation of Bcl-xL.119,120In contrast to the activation of the Jak-Stat pathway by physiologic stimuli, Bcr-Abl may directly activate Stat1 and Stat5 without prior phosphorylation of Jak proteins. There seems to be specificity for Stat6 activation by P190BCR-ABL proteins as opposed to P210BCR-ABL.115 It is tempting to speculate that the predominantly lymphoblastic phenotype in these leukemias is related to this peculiarity.

The role of the Ras and Jak-Stat pathways in the cellular response to growth factors could explain the observation that BCR-ABLrenders a number of growth factor–dependent cell lines factor independent.105,121 In some experimental systems there is evidence for an autocrine loop dependent on the Bcr-Abl–induced secretion of growth factors,122 and it was recently reported that Bcr-Abl induces an IL-3 and G-CSF autocrine loop in early progenitor cells.123 Interestingly, Bcr-Abl tyrosine kinase activity may induce expression not only of cytokines but also of growth factor receptors such as the oncostatin Mb receptor.86 One should bear in mind, however, that during the chronic phase, CML progenitor cells are still dependent on external growth factors for their survival and proliferation,124 though less than normal progeni- tors.125 A recent study sheds fresh light on this issue. FDCPmix cells transduced with a temperature-sensitive mutant ofBCR-ABL have a reduced requirement for growth factors at the kinase permissive temperature without differentiation block.126This situa- tion resembles chronic-phase CML, in which the malignant clone has a subtle growth advantage while retaining almost normal differentiation capacity.

PI3 kinase pathway.PI3 kinase activity is required for the proliferation ofBCR-ABL–positive cells.127 Bcr-Abl forms multi- meric complexes with PI3 kinase, Cbl, and the adapter molecules Crk and Crkl,95 in which PI3 kinase is activated. The next relevant substrate in this cascade appears to be the serine–threonine kinase Akt.128 This kinase had previously been implicated in anti- apoptotic signaling.129 A recent report placed Akt in the down- stream cascade of the IL-3 receptor and identified the pro-apoptotic protein Bad as a key substrate of Akt.130 Phosphorylated Bad is inactive because it is no longer able to bind anti-apoptotic proteins such as BclXL and it is trapped by cytoplasmic 14-3-3 proteins. Altogether this indicates that Bcr-Abl might be able to mimic the physiologic IL-3 survival signal in a PI3 kinase-dependent manner (see also below). Ship131 and Ship-2,132 2 inositol phosphatases with somewhat different specificities, are activated in response to growth factor signals and by Bcr-Abl. Thus, Bcr-Abl appears to have a profound effect on phosphoinositol metabolism, which might again shift the balance to a pattern similar to physiologic growth factor stimulation. Myeloid Leukemia Nursing Case Study

Myc pathway.Overexpression of Myc has been demonstrated in many human malignancies. It is thought to act as a transcription factor, though its target genes are largely unknown. Activation of Myc by Bcr-Abl is dependent on the SH2 domain, and the overexpression of Myc partially rescues transformation-defective SH2 deletion mutants whereas the overexpression of a dominant- negative mutant suppresses transformation.133The pathway linking Myc to the SH2 domain of Bcr-Abl is still unknown. However, results obtained in v-abl–transformed cells suggest that the signal is transduced through Ras/Raf, cyclin-dependent kinases (cdks), and E2F transcription factors that ultimately activate the MYC pro- moter.134 Similar results were reported for BCR-ABL–transformed murine myeloid cells.135 How these findings relate to human Ph-positive cells is unknown. It seems likely that the effects of Myc in Ph-positive cells are probably not different from those in other tumors. Depending on the cellular context, Myc may constitute a proliferative or an apoptotic signal.136,137It is therefore likely that the apoptotic arm of its dual function is counterbalanced in CML cells by other mechanisms, such as the PI3 kinase pathway.

Inhibition of apoptosis

Expression of Bcr-Abl in factor-dependent murine138 and human122 cell lines prevents apoptosis after growth-factor with- drawal, an effect that is critically dependent on tyrosine kinase activity and that correlates with the activation of Ras.88,139 More- over, several studies showed thatBCR-ABL–positive cell lines are resistant to apoptosis induced by DNA damage.89,140The underly- ing biologic mechanisms are still not well understood. Bcr-Abl may block the release of cytochrome C from the mitochondria and thus the activation of caspases.141,142 This effect upstream of caspase activation might be mediated by the Bcl-2 family of proteins. Bcr-Abl has been shown to up-regulate Bcl-2 in a Ras-143

or a PI3 kinase-dependent128 manner in Baf/3 and 32D cells, respectively. Moreover, as mentioned previously, BclxL is transcrip- tionally activated by Stat5 inBCR-ABL–positive cells.119,120

Another link betweenBCR-ABLand the inhibition of apoptosis might be the phosphorylation of the pro-apoptotic protein Bad. In addition to Akt, Raf-1, immediately downstream of Ras, phosphor- ylates Bad on 2 serine residues.144,145Two recent studies provided evidence that the survival signal provided by Bcr-Abl is at least partially mediated by Bad and requires targeting of Raf-1 to the mitochondria.146,147It is also possible that Bcr-Abl inhibits apopto- sis by down-regulating interferon consensus sequence binding protein (ICSBP).148,149These data are interesting because ICSBP knockout mice develop a myeloproliferative syndrome,150 and hematopoietic progenitor cells from ICSBP2/2 mice show altered responses to cytokines.151The connection to interferona, an active agent in the treatment of CML, is obvious. Myeloid Leukemia Nursing Case Study

It becomes clear that the multiple signals initiated by Bcr-Abl have proliferative and anti-apoptotic qualities that are frequently difficult to separate. Thus, Bcr-Abl may shift the balance toward the inhibition of apoptosis while simultaneously providing a proliferative stimulus. This is in line with the concept that a proliferative signal leads to apoptosis unless it is counterbalanced by an anti-apoptotic signal,152 and Bcr-Abl fulfills both require- ments at the same time. There is, however, controversy. One report found 32D cells transfected withBCR-ABLto be more sensitive to IR than the parental cells,153whereas 2 other studies failed to detect any difference between CML and normal primary progenitor cells with regard to their sensitivity to IR and growth factor with- drawal.124,154Furthermore, based on results obtained in transfected cell systems, it was suggested that Bcr-Abl inhibits apoptosis


D ow

nloaded from by guest on 15 M

ay 2020

mediated by the Fas receptor/Fas ligand system.155 However, though there may be a role for this system in mediating the clinical response to interferon-a,156 there is no indication that Fas-triggered apoptosis is defective in primary CML cells or in “natural” Ph-positive cell lines.157 Moreover, Bcr-Abl accelerates C2 cer- amide-induced apoptosis,158 and it does not protect against natural killer cell-induced apoptosis.159 These inconsistencies may reflect genuine differences between cell lines and primary cells. On the other hand, it is debatable whether complete growth-factor with- drawal and IR constitute stimuli that have much physiologic relevance. To allow for a representative comparison, it would be crucial to define the signals that induce apoptosis in vivo.

Degradation of inhibitory proteins.

The recent discovery that Bcr-Abl induces the proteasome- mediated degradation of Abi-1 and Abi-2,66 2 proteins with inhibitory function, may be the first indication of yet another way by which Bcr-Abl induces cellular transformation. Most compel- ling, the degradation of Abi-1 and Abi-2 is specific for Ph-positive acute leukemias and is not seen in Ph-negative samples of comparable phenotype. The overall significance of this observation remains to be seen, and one must bear in mind that the data refer to acute leukemias and not to chronic phase CML. It is nevertheless tempting to speculate that other proteins, whose level of expression is regulated through the proteasome pathway, may also be de- graded. A good candidate would be the cell cycle inhibitor p27, but to our knowledge no data are available yet.

Experimental models of CML

Various experimental systems have been developed to study the pathophysiology of CML. All of them have their advantages and shortcomings, and it is probably fair to say that there is still no ideal in vitro or in vivo model that would cover all aspects of the human disease. Myeloid Leukemia Nursing Case Study

Cell lines

Fibroblasts. Fibroblast lines have been used extensively in CML research because they are easy to manipulate. Fibroblast transforma- tion—that is, anchorage-independent growth in soft agar—is the standard in vitro test for tumorigenicity.160 However, it became clear that the introduction ofBCR-ABLinto fibroblasts has diverse effects, depending on the type of fibroblast used. Thus, though P210BCR-ABL transforms Rat-1 fibroblasts,161 there is no such effect in NIH3T3.162 Moreover, transformation to serum-independent growth occurs only in few cells (permissive cells163), whereas most undergo growth arrest. These observations show that certain cellular requirements must be met if a cell is to be transformed by BCR-ABL. Interestingly, this is also the case for the various parts of the Bcr-Abl protein. Thus, aBCR-ABLmutant that lacks the SH2 domain retains the capacity to transform hematopoietic 32D cells to growth factor independence60 but is defective for fibroblast transformation.59 In addition, there are differences between hemato- poietic cells and fibroblasts in terms of interactions with other proteins such as Crkl. The latter is functional in Ras activation and transformation in fibroblasts100 but not in hematopoietic cells.101

Thus, results obtained from studies in fibroblasts must be inter- preted with great caution.

Hematopoietic cell lines.Until relatively recently, only a few BCR-ABL–positive lines derived from CML were available, but

their number has grown considerably in the past few years.164They include cell lines with myeloid differentiation, such as the well- known K562, and lymphoid phenotype, such as BV173. The main drawback common to all these lines is the fact that they are derived from blast crisis and, thus, contain genetic lesions in addition to BCR-ABL. Consequently, they may reflect blast crisis fairly well but are insufficient models of chronic phase CML. Until now, no cell line from chronic phase CML has been established, just as no cell line could be derived from normal human bone marrow. Even attempts to immortalize Ph-positive B-cells from patients in the chronic phase of disease were not successful because these lines have a limited life span,165 in contrast to their Ph-negative counterparts. One could therefore speculate that the very establish- ment of a line from a patient with CML would be diagnostic of advanced disease. In this context, it is surprising that most human CML lines remain dependent on Bcr-Abl tyrosine kinase activity for their proliferation and survival, as shown by their susceptibility to the effects of the Abl-specific tyrosine kinase inhibitor STI571.8

However, the phenotype of these cell lines is that of an acute leukemia. Therefore great caution is warranted if experimental results are to be transferred to chronic phase CML. A striking example is the fact that inhibition of apoptosis by Bcr-Abl is easily demonstrable in cell lines139 but not in primary cells.124 It should also be noted that many of the lines used have undergone hundreds, if not thousands, of rounds of replication, and different laboratories frequently house lines that have little in common but their names andBCR-ABLpositivity. Myeloid Leukemia Nursing Case Study

Transformation of factor-dependent cell lines to growth-factor independence is an important feature of Bcr-Abl, and, in fact, other oncoproteins that contain an activated tyrosine kinase.43,166 Al- though it is usually difficult to obtain stable expression of BCR-ABLin previously immortalized cell lines, this is relatively easily achieved in factor-dependent lines, presumably because BCR-ABLexpression is an advantage to the latter but useless or even detrimental to the former. Murine cell lines such as Baf/3 and 32D and human cell lines such as MO7 were used to study the effects ofBCR-ABLby direct comparison between transduced and parental cells. A particular advantage of the murine lines is the fact that they are derived from normal nonmalignant hematopoietic cells. Unfortunately, this does not rule out the development of additional mutations167 that confer a selective growth advantage. Furthermore, it is not clear how the transformation to complete factor independence relates to clinical CML in which the cells are still factor-dependent, though obviously less so than normal hematopoietic cells.123 The subject of growth factor independence andBCR-ABLtransformation has been reviewed recently.168

None of the cell lines mentioned above is capable of multilineage hematopoietic differentiation. Two strategies are promising in overcom- ing this restraint. A recent report126 shows that murine FDCPmix cells, transduced with a temperature-sensitive mutant ofBCR-ABL, become partially factor-independent at the permissive temperature, in analogy to chronic phase CML. They retain the capacity for terminal differentia- tion, similar to chronic phase CML cells. Another approach is the study of embryonic stem (ES) cells transduced withBCR-ABL. In one such experimental system, it was possible to reproduce one cardinal feature of the clinical disease in the model, namely the expansion of the myeloid compartment at the expense of the erythroid compartment.169 Interest- ingly, the increase in total cell numbers in theBCR-ABL-transduced ES cells was found to result from increased proliferation though there was little effect on apoptosis, another finding in line with observations in primary Ph-positive cells.124,154 In this system, a stromal cell layer is used on which the ES cells removed from leukemia-inhibitory factor


D ow

nloaded from by guest on 15 M

ay 2020

(LIF) differentiate into hemangioblasts and then into hematopoietic cells. This may explain why these results are not strictly comparable to those of another study, in whichBCR-ABLresulted in the decreased formation of embryonal bodies along with increased output of all kinds of hematopoietic progenitors.170 In yet another study,BCR-ABL– transformed ES cells transplanted into irradiated mice induced a leukemic syndrome with many features of CML.171If developed further, these models may well be able to retain the major advantage of cell lines—their ease of manipulation—while at the same time moving the in vitro system closer to the clinical disease. Myeloid Leukemia Nursing Case Study

Bearing all these caveats in mind, there is no doubt that the study of cell lines contributed significantly to our understanding of CML. Particularly, many of the proteins that interact with Bcr-Abl were identified in Ph-positive cell lines, where they are more abundantly expressed than in primary cells. Thus, though these lines are invaluable tools for screening, it is important to confirm the results in primary cells.

Primary cells. The study of patient material and its comparison with normal hematopoietic progenitor cells is certainly the gold standard of CML research, particularly for the chronic phase of the disease. Much of the data refer to operationally defined cellular properties of CML versus normal cells, such as clonogenicity or adherence to bone marrow stroma; to give a comprehensive account of the cellular biology of CML would require a review in its own right. We will therefore focus on some areas in which the study of primary CML cells has been particularly instrumental to the study of the molecular biology of the disease.

One of the main problems when studying primary cells is inherent in the very nature of chronic phase cells—they tend to mature when placed in culture. Thus, the window of time for in vitro studies is narrow, and expansion of very primitive cells, the least prevalent but most interesting population, is difficult and carries the risk for introducing nonphysiologic alterations.172

Furthermore, there is considerable variation between patients that frequently results in an overlap rather than a clear distinc- tion between normal cells and CML cells. Last, results are unreliable unless clearly defined cell populations such as CD341

cells are studied. To a large extent, these problems can be overcome by the introduction of retroviralBCR-ABLexpression vectors to murine or human primary bone marrow cells (see “Animal models” below).

A striking example of how fruitful the comparison of primary cell populations can be is the study of tyrosine-phosphorylated proteins in CD341 cells.112 This study led to the subsequent identification of p62DOK74;173and SHIP2132as mediators of Bcr-Abl– induced transformation. Moreover, it produced the important notion that Bcr-Abl tyrosine kinase activity may have conse- quences similar to the activation of the KIT receptor.112 Another example is the identification of CRKL as the major tyrosine- phosphorylated protein in CML neutrophils.73

The recent possibility of turning off the Bcr-Abl tyrosine kinase activity in cell lines and primary cells with STI5717,8 provided the opportunity to study the effects of theBCR-ABL gene when expressed from its naturalBCRpromoter at “physiological” levels. This is certainly an advantage over transduced cell systems; the drawback, however, is that effects related to inhibition of the KIT and PDGFRb kinases, and potentially other unidentified tyrosine kinases, cannot be ruled out. Furthermore, the Bcr-Abl protein, though kinase-inactive, is still present in the cells and may interfere with other proteins.

Animal models

Thus far, no animals other than mice have been used for the study of CML in vivo. Various approaches have been taken.

Engraftment of BCR-ABL–transformed cell lines in synge- neic mice. Murine factor-dependent cell lines such as 32D trans- duced withBCR-ABLgive rise to an aggressive leukemia when transplanted into syngeneic recipients.60,174This is an excellent in vivo model to test the efficacy of new drugs, such as the tyrosine kinase inhibitor STI571, in vivo. Furthermore, the impact on leukemogenicity of modifications within the Bcr-Abl protein and modifications to the respective cell lines (such as the introduction of co-stimulatory molecules174) can be tested. The main drawback is that the disease is a form of acute leukemia and is thus far from chronic phase CML.

Engraftment of immunodeficient mice with human BCR-ABL– positive cells.Cell lines derived from human CML blast crisis are relatively easily propagated in severe combined immunodeficiency (SCID) mice.175 The distribution of the leukemia cells is fairly similar to the human disease, that is, they home to bone marrow and peripheral blood before they metastasize to nonhematopoietic tissues. More recently, it was shown that SCID mice can be engrafted with chronic phase CML cells if the cell inoculum is large enough (in the range of 13 108 cells).176 Up to 10% human cells were detectable in the recipient bone marrow and showed multilineage differentiation. Interestingly, most colonies were BCR-ABL negative and thus were derived from the patient’s residual normal hematopoiesis. This is reminiscent of long-term bone marrow cultures of CML177 and shows that host factors modify the disease to a great extent, a problem that will persist, even if higher percentages of engraftment can eventually be achieved. A step into this direction is the use of nonobese diabetes-SCID mice. In addition to the SCID defect in V(D)J recombination, these animals lack functional natural killer cells. Chronic phase CML cells and, even more so, cells from accelerated phase or blast crisis readily engraft in these mice, and there is a significant correlation between engraftment and disease state.178

Interestingly, the cells were exclusively Ph-positive in most cases, in contrast to cells engrafted in SCID mice, as mentioned above. This may be attributed to technical reasons but may also reflect a genuine difference between the different strains of mice. We can anticipate that these murine models will be useful for studying certain aspects of CML, such as the response to novel forms of treatment. Their value in investigating the human disease will be limited because it is difficult to see how disease modification by host factors could ever be ruled out. Myeloid Leukemia Nursing Case Study

Transgenic mouse models.Attempts to useBCR-ABLtrans- genic mice as a CML model go back to the late 1980s, when a full-length cDNA of BCR-ABL was not yet available and an artificial construct of human BCR sequences fused to v-abl was used instead.179 Since then, a number of studies have been published that clearly prove the oncogenic potential ofBCR-ABL. Several different promoters were used to direct the expression to the desired target tissues. However, some problems were encoun- tered. First, it became clear that Bcr-Abl has a toxic effect on embryogenesis,180 perhaps the consequence of a cytostatic effect in nonhematopoietic tissues.181 Recently, the expression ofBCR-ABL from a tetracycline-repressible promoter effectively overcame this problem.182 Most striking, the leukemia in these transgenic mice is completely reversible on re-addition of tetracycline. The second problem with transgenic mice is that the P210BCR-ABLvariant relevant to CML is difficult to study because it is less efficient in


D ow

nloaded from by guest on 15 M

ay 2020

inducing leukemia than P190, a finding that was again confirmed in a recent study.47 Third and most important, the types of leukemia that developed in these mice were acute and of either B- or T-lymphoid phenotype, regardless of whether they arose in P190 or P210 transgenic animals. Thus, they resembledBCR-ABL–positive ALL but not chronic-phase CML183,184. In fact, myeloid leukemias developed rarely, if at all. A recent report185 may represent a major advance in this respect. In this study,BCR-ABLwas expressed from the Tec promoter, a cytoplasmic tyrosine kinase predominantly expressed in hematopoietic cells. Although the founder mice exhibited excessive proliferation of lymphoblasts, their progeny developed a CML-like disease, albeit after a relatively long latency period of approximately 10 months. Thus, it is likely that the problems of the transgenic models will eventually be resolved if the gene is targeted to the appropriate cell. Myeloid Leukemia Nursing Case Study

Transduction of murine bone marrow cells with BCR-ABL retroviruses. In 1990, several groups reported that a CML-like myeloproliferative syndrome could be induced when P210BCR- ABL–infected marrow was transplanted into syngeneic recipi- ents.6,186,187 Transplantation into secondary recipients frequently produced an identical disease while some mice developed acute leukemias of T- or B-cell phenotype, analogous to the development of lymphoid blast crisis in the clinical disease. Clonality was demonstrated in many cases. Roughly a quarter of the mice showed the myeloproliferative disease, whereas other recipients developed other distinct hematologic malignancies, such as macrophage tumors, B-ALL, T-ALL, and erythroleukemia. Most likely, these different diseases are the consequence of infection of different committed progenitor cells that, after transformation, give rise to the respective progeny. Not surprisingly, the infection conditions have a major impact on the disease phenotype.188 Building on the foundations of this early work, major improvements to the transduction–transplantation system have been made in the past few years. High-titerBCR-ABLretroviral stocks can be produced rapidly by transient transfection of packaging lines; the culture conditions have been refined, and the murine stem cell virus LTR has been introduced that allows for more efficient expression of BCR-ABLin the desired target cell. Combining all 3 improvements, 2 recent studies189,190 reported the induction of a transplantable CML-like disease in 100% of recipients. Pulmonary hemorrhage, a complication not found in human CML, was a frequent cause of death in both studies, demonstrating that these novel models, though a major step forward, may have their own distinct problems. Nevertheless, bone marrow transduction–transplantation most faith- fully reproduces human CML, and further improvements are likely in the near future.

Transformation to blast crisis

Clinically, chronic-phase CML does not represent a major manage- ment problem because the elevated white blood cell count is readily controlled with cytotoxic agents in most patients, and neutrophil and platelet functions are largely normal. However, the disease progresses inexorably to acceleration and blast crisis, often within 5 years of diagnosis. The mechanisms underlying this evolution remain enigmatic. Deletion or inactivation of p16,191 p53,192 and the retinoblastoma gene product193 have been reported but occur relatively rarely and, similar to the overexpression ofEVI-1,194 are not specific for blast crisis CML. This probably indicates that a wide variety of lesions, possibly multiple “cooperating” lesions, are required to induce the phenotype of blast crisis. Perhaps even

more intriguing is why the cells acquire these additional lesions in the first place. A recent report shows that Bcr-Abl enhances the mutation rate in the Na-K-ATPase and in the HPRT genomic loci, both commonly used markers to measure mutation frequency. Along with this goes enhanced expression of DNA polymeraseb, the mammalian DNA polymerase with the least fidelity.195P210BCR-

ABL, but not P190BCR-ABL, phosphorylates and potentially interacts with xeroderma pigmentosum group B protein (XPB); as a result, the catalytic function of XPB may be reduced, and DNA repair may be impaired.196 In a recent study p210BCR-ABL transgenic mice were cross-mated with p53 heterozygous mice. In the offspring, the remaining p53 was rapidly lost because of somatic mutation, and the mice developed a disease that resembled blast crisis.197

Although this is still not a perfect model of human CML because the blasts are of T lineage, it strongly supports the concept of genomic instability inBCR-ABL–transformed cells. How Bcr-Abl leads to these phenomena is unclear, but they might form the basis of the presumed genomic instability of chronic phase CML. It is also possible that the alleged anti-apoptotic effect of Bcr-Abl favors inaccurate DNA repair where apoptosis would ensue in normal cells. In line with this concept, a prolonged G2 arrest after IR has been observed inBCR-ABL–expressing cell lines exposed to DNA-damaging agents.140This arrest could allow for DNA (mis)re- pair, whereas in a normal cell the damage would induce apoptosis. Over time this could lead to the accumulation of mutations in BCR-ABL–positive cells that finally result in blastic transforma- tion. There is no doubt that the excessive proliferation, with its high cell turnover, must be a risk factor per se for additional ge- netic lesions. Myeloid Leukemia Nursing Case Study

Molecular targets for therapy

Attempts at designing therapeutic tools for CML based on our current knowledge of the molecular and cell biology of the disease have concentrated on 3 main areas—the inhibition of gene expression at the translational level by “antisense” strategies, the stimulation of the immune system’s capacity to recognize and destroy leukemic cells, and the modulation of protein function by specific signal transduction inhibitors. The antisense oligonucleo- tide198,199and ribozyme200 approaches received much attention in the last decade but have in general failed to fulfill their theoretical promises. New modifications to the system, such as the use of BCR-ABLjunction-specific catalytic subunits of RNase P,201 may revitalize the field. The issue of immunologic stimulation, be it in the form of adoptive immunotherapy by donor lymphocyte infu- sions202 or of BCR-ABLjunction peptide vaccination,203 is another avenue being extensively explored for the treatment of CML.

Perhaps the most exciting of the molecularly designed therapeu- tic approaches was brought about by the advent of signal transduc- tion inhibitors (STI), which block or prevent a protein from exerting its role in the oncogenic pathway. Because the main transforming property of the Bcr-Abl protein is effected through its constitutive tyrosine kinase activity, direct inhibition of such activity seems to be the most logical means of silencing the oncoprotein. To this effect, several tyrosine kinase inhibitors have been evaluated for their potential to modify the phenotype of CML cells. The first to be tested were compounds isolated from natural sources, such as the iso-flavonoid genistein and the antibiotic herbimycin A.204 Later, synthetic compounds were developed through a rational design of chemical structures capable of competing with the adenosine triphosphate (ATP) or the protein


D ow

nloaded from by guest on 15 M

ay 2020

substrate for the binding site in the catalytic center of the kinase205

(Figure 7). The most promising of these compounds is the 2-phenylamin-

opyrimidine STI571 (formerly CGP57418B; Novartis Pharmaceu- tics, Basel, Switzerland), which specifically inhibits Abl tyrosine kinase at micromolar concentrations.206 Inhibition of the Bcr-Abl kinase activity by this compound results in the transcriptional modulation of various genes involved in the control of the cell cycle, cell adhesion, and cytoskeleton organization, leading the Ph-positive cell to an apoptotic death.86 Furthermore, STI571 selectively suppresses the growth of CML primary cells and cell lines in vitro7,8 and in mice.7,207 Its remarkable specificity and efficacy led to consideration of the drug for therapeutic use. Thus, in the spring of 1998, a phase 1 clinical trial was initiated in the United States in which patients with CML in chronic phase resistant to IFN-a were treated with STI571 in increasing doses. The drug showed little toxicity but proved to be highly effective. All patients treated with 300 mg/d or more entered a complete hematologic remission. Even more striking, many of the patients had cytogenetic responses.9 This might mean that STI571 changes the natural course of the disease, though it is far too early to arrive at any definite conclusions. Altogether, the results were convincing enough to justify the initiation of phase 2 studies that included patients with acute Ph-positive leukemias (CML in blast crisis and Ph-positive ALL) and, at a later stage, a large cohort of interferon- intolerant or -resistant patients. These studies are ongoing. It turned out that STI571 is effective in many patients with acute Ph-positive leukemia, particularly of lymphoid phenotype. Although in many patients the remissions are not sustained, the advent of an effective oral medication with little toxicity represents a major step forward in this very poor risk group. Clearly, elucidation of the mechanisms underlying the resistance208 will be of critical importance for the development of further treatment strategies, such as a combination of STI571 with conventional cytotoxic drugs or, perhaps, with other STIs (see below). In this context, the most interesting question is whether STI571 will be able to eradicate the malignant clone, at least in some patients with chronic-phase CML. From what we know about the disease, this seems unlikely—colony formation by CML progenitor cells is much reduced but not abrogated in the presence of STI5717,8—which might mean that a subset of these cells proliferates independently of Bcr-Abl tyrosine

kinase activity and still relies on external growth factors. There is no doubt, however, that the clinical efficacy and low toxicity of STI571 sets a precedent for the further development of targeted forms of therapy in malignant disease.

An alternative or a supplement to direct inhibition of Bcr-Abl is interference with proteins that are critical for Bcr-Abl–induced transformation (Figure 4). One of these proteins is Grb2, whose SH2 domain binds directly to Bcr-Abl through the phosphorylated tyrosine 177 within the Bcr portion of the chimera57 and is essential for activation of the Ras pathway (Figure 6).209 Another good candidate is Ras itself, whose activity depends on its attachment to the cell membrane through a prenyl (usually a farnesyl) group. Thus, farnesyl transferase inhibitors (FTI) have been studied for their effect in inhibiting the proliferation of ALL210 and juvenile myelomonocytic leukemia cells,211 and they may be useful for the control of CML cells. Additional targets worth considering are represented by PI-3 and Src kinases, of which the available inhibitors have been shown to suppress colony formation of primary progenitors,127 proliferation ofBCR-ABL–transfected cell lines, or both.212,213It is envisaged that the progressive unraveling of which pathways are really essential for the development of the disease, coupled to rapid advances in biotechnology, will bring us the ideal combination of rationally designed drugs that can tip the balance toward the re-establishment of normal hematopoiesis in CML. Myeloid Leukemia Nursing Case Study


Though this be madness, yet there is method in it.(Shakespeare W., Hamlet.Act 2, scene 2.)

There are 2 ways to conclude this review after going through the vast amount of data presented. Surely one could argue that despite all these data, there is still no clear picture emerging and each piece of additional information adds only more confusion. Alternatively, what might help us against capitulation in the face of complexity is to try to simplify without oversimplification.

Can we build a model of CML that incorporates all the scientific data available but still retains clarity? In other words, could we explain how Bcr-Abl works in a few sentences to somebody who has never heard of it? Perhaps the most promising approach might be to try to link the biologic behavior of a CML cell to the underlying molecular events (Figure 5). Crucially, we should be able to picture this scenario relying onBCR-ABLalone because, at least until now, there is no unequivocal evidence that additional genetic lesions are present during chronic phase. We do not know how long it takes to move from the initial genetic event to fully established chronic-phase CML, but there is good reason to believe that the proliferative advantage of CML over normal cells is limited. Together with the largely normal differentiation capacity and function of CML blood cells, one feels that Ph-positive hematopoiesis cannot be so much different from normal hematopoi- esis until the disease accelerates. Thus, Bcr-Abl is likely to hijack pathways that normally increase blood cell output in response to physiologic stimuli rather than to interrupt or replace them with pathways that are not normally used in hematopoietic cells. Indeed, there is plenty of experimental evidence to support this notion. Importantly, Bcr-Abl is capable of activating survival pathways along with proliferative stimuli without the need for a second cooperating genetic lesion; in this way, the apoptotic response that would otherwise follow an isolated proliferative stimulus is

Figure 7. Mechanism of action of tyrosine kinase inhibitors. The drug competes with ATP for its specific binding site in the kinase domain. Thus, whereas the physiologic binding of ATP to its pocket allows Bcr-Abl to phosphorylate selected tyrosine residues on its substrates (left diagram), a synthetic ATP mimic such as STI571 fits this pocket equally well but does not provide the essential phosphate group to be transferred to the substrate (right diagram). The downstream chain of reactions is then halted because, with its tyrosines in the unphosphorylated form, this protein does not assume the necessary conformation to ensure association with its effector.


D ow

nloaded from by guest on 15 M

ay 2020

avoided. The sustained dependence on growth factors is an indication that Bcr-Abl is not a complete substitute; rather, it tips the balance to provide a limited growth advantage in vivo. This growth advantage is also dependent on specific survival conditions: transient regeneration of Ph-negative hematopoiesis is often ob- served after autografting, even when the autograft seems to be comprised exclusively of Ph-positive stem cells, and long-term cultures initiated from patients with chronic-phase CML become dominated byBCR-ABL–negative cells after some time.177 Thus, there appears to be a specific interaction (or noninteraction) of CML progenitor cells with their microenvironment that is crucial to maintain their proliferative advantage. Whether this interaction is stimulatory for CML over normal progenitor cells or inhibitory for normal over CML progenitor cells remains to be seen. Similarly, we can look at extramedullary hematopoiesis as a loss of function (ie, loss of the capacity to respond to negative signals) or a gain of function (ie, acquisition of a capacity to respond to positive signals that are not provided in the bone marrow) phenomenon. Much of the evidence implicates integrins in mediating these abnormal interactions, but other proteins may also play a role. Overall, it appears that the organization of cell membrane and cytoskeleton is more profoundly perturbed in CML progenitor cells than might be anticipated from the largely normal function of their progeny. Furthermore, Bcr-Abl may interfere with the “wiring” between integrin receptors on the cell surface and the nucleus and so disturb the communication of the cell with its environment. Another mechanism may also be important: Bcr-Abl appears to induce the degradation of certain inhibitory proteins. This might thwart cellular counter-reactions that would otherwise be activated, rather like cutting the telephone cable before the police can be called in. Myeloid Leukemia Nursing Case Study

Many questions remain unanswered. Why is there a predomi- nantly myeloid expansion when all 3 lineages carry the translo-

cation? What is the biologic basis for the extraordinary variabil- ity in the clinical course of a disease that appears to carry just a single genetic lesion? What is the molecular basis for the genomic instability that we see clinically as relentless progres- sion to blast crisis?

Where do we go from here? The more we learn about the pathogenesis of CML, the more we realize its extraordinary complexity. Perhaps one should not be too surprised because it has become clear that cellular processes tend to rely on integrated networks rather than on straight unidirectional path- ways. Only in this way can the cell achieve the flexibility required to respond to the various stimuli within a multicellular organism. Clearly, some components must be more important, and some less so, in the transformation network operated by Bcr-Abl. Absolutely essential features may be restricted to functional domains and to certain residues of the Bcr-Abl protein itself, and downstream effectors may be able to substi- tute for each other, at least to some extent. In this respect, the use of knockout mice that lack specific downstream molecules will allow one to define their precise relevance for Bcr-Abl– mediated cellular transformation. It may turn out that the combined elimination of several components abrogates transfor- mation by Bcr-Abl, whereas each component individually is of limited significance. Chronic phase CML operates very much by exploiting physiologic pathways, perhaps by gently “coaxing” hematopoiesis toward the classical CML phenotype; neverthe- less it prepares the ground for blast crisis. Thus, to understand CML, we must study its chronic phase. We must move away from artificial systems, such as transduced fibroblasts, and take on the demanding task of studying signal transduction in primary progenitor cells. Myeloid Leukemia Nursing Case Study


1. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.

2. Rowley JD. A new consistent chromosomal ab- normality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973;243:290-293.

3. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306: 277-280.

4. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99.

5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation po- tency of bcr-abl oncogene products. Science. 1990;247:1079-1082.

6. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromo- some. Science. 1990;247:824-830.

7. Druker BJ, Tamura S, Buchdunger E, et al. Ef- fects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.

8. Deininger M, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selec- tively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90:3691-3698.

9. Druker BJ, Talpaz M, Resta D, et al. Clinical effi- cacy and safety of an ABL-specific tyrosine ki-

nase inhibitor as targeted therapy for chronic my- eloid leukemia [abstract]. Blood. 1999:94:368.

10. Abelson HT, Rabstein LS. Lymphosarcoma: vi- rus-induced thymic-independent disease in mice. Cancer Res. 1970;30:2213-2222.

11. Laneuville P. Abl tyrosine protein kinase. Semin Immunol. 1995;7:255-266.

12. Cohen GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell. 1995;80:237-248.

13. Feller SM, Knudsen B, Hanafusa H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994;13:2341-2351.

14. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell. 1989;58:669-678.

15. Kipreos ET, Wang JY. Cell cycle-regulated bind- ing of c-Abl tyrosine kinase to DNA. Science. 1992;256:382-385.

16. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl onco- protein of Philadelphia chromosome-positive hu- man leukemias. EMBO J. 1993;12:1533-1546.

17. Kipreos ET, Wang JY. Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity. Science. 1990;248:217-220.

18. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-Abl nega- tively regulates cell growth. Cell. 1994;77:121- 131.

19. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regu- lated by tyrosine kinase c-Abl in the apoptotic re-

sponse to DNA damage. Nature. 1999;399:814- 817.

20. Lewis JM, Schwartz MA. Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem. 1998;273:14225-14230.

21. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 1999; 9:179-186.

22. Tybulewicz VL, Crawford CE, Jackson PK, Bron- son RT, Mulligan RC. Neonatal lethality and lym- phopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65:1153- 1163.

23. Schwartzberg PL, Stall AM, Hardin JD, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell. 1991;65:1165-1175.

24. Reuther GW, Fu H, Cripe LD, Collier RJ, Pender- gast AM. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science. 1994;266:129-133.

25. McWhirter JR, Galasso DL, Wang JY. A coiled- coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587-7595.

26. Denhardt DT. Signal-transducing protein phos- phorylation cascades mediated by Ras/Rho pro- teins in the mammalian cell: the potential for mul- tiplex signalling. Biochem J. 1996;318:729-747.

27. Montaner S, Perona R, Saniger L, Lacal JC. Mul- tiple signaling pathways lead to the activation of the nuclear factor kB by the Rho family of GTPases. J Biol Chem. 1998;273:12779-12785.

28. Diekmann D, Brill S, Garrett MD, et al. Bcr en- codes a GTPase-activating protein for p21rac. Nature. 1991;351:400-402.


D ow

nloaded from by guest on 15 M

ay 2020

29. Diekmann D, Nobes CD, Burbelo PD, Abo A, Hall A. Rac GTPase interacts with GAPs and target proteins through multiple effector sites. EMBO J. 1995;14:5297-5305.

30. Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene. 1998; 16:141-146.

31. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. On- cogene. 1997;14:2367-2372.

32. Liu J, Wu Y, Ma GZ, et al. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol. 1996;16:998-1005.

33. Voncken JW, van Schaick H, Kaartinen V, et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell. 1995;80:719-728.

34. Voncken JW, Kaartinen V, Groffen J, Heisterkamp N. Bcr/Abl associated leukemogenesis in bcr null mutant mice. Oncogene. 1998;16:2029-2032.

35. Melo JV. The diversity of BCR-ABL fusion pro- teins and their relationship to leukemia pheno- type. Blood. 1996;88:2375-2384.

36. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leuke- mia? Leukemia. 1994;8:208-211.

37. Ravandi F, Cortes J, Albitar M, et al. Chronic my- elogenous leukaemia with p185(BCR/ABL) ex- pression: characteristics and clinical significance. Br J Haematol. 1999;107:581-586.

38. Pane F, Frigeri F, Sindona M, et al. Neutrophilic- chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88:2410-2414.

39. Wilson G, Frost L, Goodeve A, Vandenberghe E, Peake I, Reilly J. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia. Blood. 1997;89:3064.

40. van Rhee F, Hochhaus A, Lin F, Melo JV, Gold- man JM, Cross NC. p190 BCR-ABL mRNA is ex- pressed at low levels in p210-positive chronic my- eloid and acute lymphoblastic leukemias. Blood. 1996;87:5213-5217.

41. Melo JV. BCR-ABL gene variants. Baillieres.Clin- .Haematol. 1997;10:203-222.

42. Leibundgut EO, Jotterand M, Rigamonti V, et al. A novel BCR-ABL transcript e2a2 in a chronic my- elogenous leukaemia patient with a duplicated Ph-chromosome and monosomy 7. Br J Haema- tol. 1999;106:1041-1044.

43. Golub TR, Goga A, Barker GF, et al. Oligomeriza- tion of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996;16: 4107-4116.

44. Papadopoulos P, Ridge SA, Boucher CA, Stock- ing C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Can- cer Res. 1995;55:34-38.

45. Cazzaniga G, Tosi S, Aloisi A, et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood. 1999;94:4370-4373.

46. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic my- eloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399-1412.

47. Quackenbush RC, Reuther GW, Miller JP, Court- ney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the onco- genic p185 and p210 Bcr-Abl tyrosine kinases. Blood. 2000;95:2913-2921.

48. Tanaka K, Takechi M, Hong J, et al. 9;22 translo- cation and bcr rearrangements in chronic myelo- cytic leukemia patients among atomic bomb sur- vivors. J Radiat Res. 1989;30:352-358.

49. Corso A, Lazzarino M, Morra E, et al. Chronic my- elogenous leukemia and exposure to ionizing ra- diation—a retrospective study of 443 patients. Ann Hematol. 1995;70:79-82. Myeloid Leukemia Nursing Case Study

50. Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, Melo JV. Selective induction of leu- kemia-associated fusion genes by high-dose ion- izing radiation. Cancer Res. 1998;58:421-425.

51. Kozubek S, Lukasova E, Ryznar L, et al. Distribu- tion of ABL and BCR genes in cell nuclei of nor- mal and irradiated lymphocytes. Blood. 1997;89: 4537-4545.

52. Neves H, Ramos C, da Silva MG, Parreira A, Par- reira L. The nuclear topography of ABL, BCR, PML, and RARa genes: evidence for gene prox- imity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood. 1999;93:1197-1207.

53. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of BCR-ABL fusion genes in leukocytes of normal individuals: impli- cations for the assessment of minimal residual disease. Blood. 1998;92:3362-3367.

54. Biernaux C, Sels A, Huez G, Stryckmans P. Very low level of major BCR-ABL expression in blood of some healthy individuals. Bone Marrow Trans- plant. 1996;17(suppl 3):S45–S47.

55. Posthuma EF, Falkenburg JH, Apperley JF, et al. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the develop- ment of chronic myeloid leukemia: the Chronic Leukemia Working Party of the EBMT. Blood. 1999;93:3863-3865.

56. Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Ja- cobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 1981;58:158-163.

57. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185.

58. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transfor- mation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphoty- rosine-dependent manner. Cell. 1991;66:161- 171.

59. Afar DE, Goga A, McLaughlin J, Witte ON, Saw- yers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science. 1994;264: 424-426.

60. Ilaria RL Jr, Van Etten RA. The SH2 domain of P210BCR/ABL is not required for the transforma- tion of hematopoietic factor-dependent cells. Blood. 1995;86:3897-3904.

61. Mayer BJ, Baltimore D. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. Mol Cell Biol. 1994;14: 2883-2894.

62. Danial NN, Pernis A, Rothman PB. Jak-STAT sig- naling induced by the v-abl oncogene. Science. 1995;269:1875-1877.

63. Shi Y, Alin K, Goff SP. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal por- tion of the Abl protein, suppresses v-abl trans- forming activity. Genes Dev. 1995;9:2583-2597.

64. Dai Z, Pendergast AM. Abi-2, a novel SH3-con- taining protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 1995;9:2569-2582.

65. Cicchetti P, Mayer BJ, Thiel G, Baltimore D. Iden- tification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science. 1992;257:803-806.

66. Dai Z, Quackenbush RC, Courtney KD, et al. On- cogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target pro- teins through a Ras-independent pathway. Genes Dev. 1998;12:1415-1424.

67. Wen ST, Van ER. The PAG gene product, a stress-induced protein with antioxidant proper-

ties, is an Abl SH3-binding protein and a physio- logical inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 1997;11:2456-2467.

68. Goga A, McLaughlin J, Pendergast AM, et al. On- cogenic activation of c-ABL by mutation within its last exon. Mol Cell Biol. 1993;13:4967-4975.

69. Jackson PK, Paskind M, Baltimore D. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Oncogene. 1993;8:1943-1956.

70. Janssen JW, Ridge SA, Papadopoulos P, et al. The fusion of TEL and ABL in human acute lym- phoblastic leukaemia is a rare event. Br J Haematol. 1995;90:222-224.

71. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the 1(8;13)(p11;q12) myeloprolifera- tive syndrome. Blood. 1998;92:1735-1742.

72. Golub TR, Barker GF, Lovett M, Gilliland DG. Fu- sion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.

73. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phos- phorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994;269:22925-22928.

74. Carpino N, Wisniewski D, Strife A, et al. p62(dok): a constitutively tyrosine-phosphorylated, GAP- associated protein in chronic myelogenous leuke- mia progenitor cells. Cell. 1997;88:197-204.

75. Matsuguchi T, Salgia R, Hallek M, et al. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating fac- tor, interleukin-3, and steel factor and is constitu- tively increased by p210BCR/ABL. J Biol Chem. 1994;269:5016-5021.

76. Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion pro- teins in myeloid cell lines expressing p210BCR/ ABL. Oncogene. 1995;11:1149-1155.

77. Salgia R, Li JL, Lo SH, et al. Molecular cloning of human paxillin, a focal adhesion protein phos- phorylated by P210BCR/ABL. J Biol Chem. 1995; 270:5039-5047.

78. Gotoh A, Miyazawa K, Ohyashiki K, et al. Ty- rosine phosphorylation and activation of focal ad- hesion kinase (p125FAK) by BCR-ABL oncopro- tein. Exp Hematol. 1995;23:1153-1159.

79. Ernst TJ, Slattery KE, Griffin JD. p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem. 1994; 269:5764-5769.

80. Gotoh A, Miyazawa K, Ohyashiki K, Toyama K. Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph-posi- tive ALL involve GTPase-activating protein, phos- pholipase C-gamma 1, and phosphatidylinositol 3’-kinase. Leukemia. 1994;8:115-120.

81. Andoniou CE, Thien CB, Langdon WY. Tumour induction by activated abl involves tyrosine phos- phorylation of the product of the cbl oncogene. EMBO J. 1994;13:4515-4523.

82. Matsuguchi T, Inhorn RC, Carlesso N, Xu G, Druker B, Griffin JD. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively in- creased by p210BCR/ABL. EMBO J. 1995;14: 257-265.

83. Tauchi T, Feng GS, Shen R, et al. SH2-containing phosphotyrosine phosphatase Syp is a target of p210 bcr-abl tyrosine kinase. J Biol Chem. 1994; 269:15381-15387.

84. LaMontagne KR Jr, Flint AJ, Franza BR Jr, Pan- dergast AM, Tonks NK. Protein tyrosine phospha- tase 1B antagonizes signaling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol Cell Biol. 1998;18:2965-2975.

85. LaMontagne KR Jr, Hannon G, Tonks NK. Protein tyrosine phosphatase PTP1B suppresses p210


D ow

nloaded from by guest on 15 M

ay 2020

bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. Proc Natl Acad Sci U S A. 1998;95:14094-14099.

86. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine ki- nase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 2000;60:2049- 2055.

87. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature. 1987;328: 342-344.

88. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-773.

89. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994;83:2038- 2044.

90. Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bha- tia R. Integrin-mediated regulation of hematopoi- esis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol. 1997;97:40-52.

91. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest. 1994;94:384-391.

92. Zhao RC, Tarone G, Verfaillie CM. Presence of the adhesion inhibitory b1B integrin isoform on CML but not normal progenitors is at least in part responsible for the decreased CML progenitor adhesion [abstract]. Blood. 1997;90:393a.

93. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A. 1996;93:15174-15179.

94. Uemura N, Griffin JD. The adapter protein Crkl links Cbl to C3G after integrin ligation and en- hances cell migration. J Biol Chem. 1999;274: 37525-37532.

95. Sattler M, Salgia R, Okuda K, et al. The proto- oncogene product p120CBL and the adaptor pro- teins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3’ kinase pathway. Oncogene. 1996;12:839-846.

96. Salgia R, Pisick E, Sattler M, et al. p130CAS forms a signaling complex with the adapter pro- tein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996;271: 25198-25203.

97. Sattler M, Salgia R, Shrikhande G, et al. Differen- tial signaling after b1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997;272:14320- 14326.

98. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996;98: 521-528.

99. Pelicci G, Lanfrancone L, Salcini AE, et al. Con- stitutive phosphorylation of Shc proteins in hu- man tumors. Oncogene. 1995;11:899-907. Myeloid Leukemia Nursing Case Study

100. Senechal K, Halpern J, Sawyers CL. The CRKL adaptor protein transforms fibroblasts and func- tions in transformation by the BCR-ABL onco- gene. J Biol Chem. 1996;271:23255-23261.

101. Heaney C, Kolibaba K, Bhat A, et al. Direct bind- ing of CRKL to BCR-ABL is not required for BCR- ABL transformation. Blood. 1997;89:297-306.

102. Watzinger F, Gaiger A, Karlic H, Becher R, Pill- wein K, Lion T. Absence of N-ras mutations in my- eloid and lymphoid blast crisis of chronic myeloid leukemia. Cancer Res. 1994;54:3934-3938.

103. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activa-

tion by tyrosine phosphorylation. EMBO J. 1995; 14:3136-3145.

104. Cahill MA, Janknecht R, Nordheim A. Signalling pathways: jack of all cascades. Curr Biol. 1996;6: 16-19.

105. Kabarowski JH, Allen PB, Wiedemann LM. A tem- perature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 1994;13:5887-5895.

106. Cortez D, Reuther GW, Pendergast AM. The BCR-ABL tyrosine kinase activates mitotic signal- ing pathways and stimulates G1-to-S phase tran- sition in hematopoietic cells. Oncogene. 1997;15: 2333-2342.

107. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11746-11750.

108. Skorski T, Wlodarski P, Daheron L, et al. BCR/ ABL-mediated leukemogenesis requires the ac- tivity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A. 1998;95:11858-11862.

109. Shi C-S, Tuscano JM, Witte O, Kehrl JH. GCKR links the BCR-ABL oncogene and RAS to the stress-activated protein kinase pathway. Blood. 1999;93:1338-1345.

110. Wilson Rawls J, Xie S, Liu J, Laneuville P, Arling- haus RB. P210 Bcr-Abl interacts with the interleu- kin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res. 1996;56:3426-3430.

111. Hallek M, Danhauser Riedl S, Herbst R, et al. In- teraction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 1996;94:5-16.

112. Wisniewski D, Strife A, Berman E, Clarkson B. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progeni- tors that are constitutively phosphorylated in com- parable primitive progenitors in chronic phase chronic myelogenous leukemia. Leukemia. 1996; 10:229-237.

113. Di Cristofano A, Carpino N, Dunant N, et al. Mo- lecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem. 1998;273:4827-4830.

114. Bhat A, Johnson KJ, Oda T, Corbin AS, Druker BJ. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins. J Biol Chem. 1998;273:32360-32368.

115. Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704- 31710.

116. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-ex- pressing cell lines and peripheral blood cells de- rived from leukemic patients. J Immunol. 1997; 159:4720-4728.

117. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 1999;94:1108-1112.

118. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999;18:4754- 4765.

119. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by sup- pressing signal transducer and activator of tran- scription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191:977-984.

120. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000; 95:2118-2125.

121. Daley GQ, Baltimore D. Transformation of an in- terleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.

122. Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-dependent growth of hu- man hematopoietic M07E cells by an autocrine mechanism. Blood. 1994;83:1575-1585.

123. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12804-12809.

124. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. Apoptosis in chronic myeloid leukaemia: normal responses by pro- genitor cells to growth factor deprivation, X-irra- diation and glucocorticoids. Br J Haematol. 1995; 91:387-393.

125. Jonuleit T, Peschel C, Schwab R, et al. Bcr-Abl kinase promotes cell cycle entry of primary my- eloid CML cells in the absence of growth factors. Br J Haematol. 1998;100:295-303.

126. Pierce A, Owen-Lynch PJ, Spooncer E, Dexter TM, Whetton AD. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leu- kaemia. Oncogene. 1998;17:667-672.

127. Skorski T, Kanakaraj P, Nieborowska Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.

128. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-de- pendent pathway. EMBO J. 1997;16:6151-6161.

129. Franke TF, Kaplan DR, Cantley LC. PI3K: down- stream AKTion blocks apoptosis. Cell. 1997;88: 435-437.

130. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphoryla- tion of bad through the protein kinase akt. Science. 1998;278:687-689.

131. Lioubin MN, Algate PA, Tsai S, Carlberg K, Aeber- sold A, Rohrschneider LR. p150Ship, a signal transduction molecule with inositol polyphos- phate-5-phosphatase activity. Genes Dev. 1996; 10:1084-1095.

132. Wisniewski D, Strife A, Swendeman S, et al. A novel SH2-containing phosphatidylinositol 3,4,5- trisphosphate 5-phosphatase (SHIP2) is constitu- tively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood. 1999;93:2707-2720.

133. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL on- cogenes. Cell. 1992;70:901-910.

134. Zou X, Rudchenko S, Wong K, Calame K. Induc- tion of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases. Genes Dev. 1997;11:654-662.

135. Stewart MJ, Litz Jackson S, Burgess GS, Wil- liamson EA, Leibowitz DS, Boswell HS. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation: studies in murine myeloid cells. Leukemia. 1995;9:1499-1507.

136. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is in- hibited by bcl-2. Nature. 1992;359:552-554.

137. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119-128.

138. Daley GQ, Baltimore D. Transformation of an in- terleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1992;85:9312-9316.

139. Cortez D, Kadlec L, Pendergast AM. Structural


D ow

nloaded from by guest on 15 M

ay 2020

and signaling requirements for BCR-ABL-medi- ated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.

140. Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-me- diated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86:1148-1158.

141. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis up- stream of procaspase-3 activation. Blood. 1998; 91:2415-2422.

142. Amarante Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mi- tochondrial release of cytochrome C and activa- tion of caspase-3. Blood. 1998;91:1700-1705.

143. Sanchez Garcia I, Martin Zanca D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol. 1997;267:225-228.

144. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996; 87:629-638.

145. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87:619-628.

146. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidyl- inositol 3-kinase and Raf. Mol Cell Biol. 2000;20: 1179-1186.

147. Majewski M, Nieborowska-Skorska M, Salomoni P, et al. Activation of mitochondrial Raf-1 is in- volved in the antiapoptotic effects of Akt. Cancer Res. 1999;59:2815-2819.

148. Gabriele L, Phung J, Fukumoto J, et al. Regula- tion of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med. 1999;190:411-421.

149. Hao SX, Ren R. Expression of interferon consen- sus sequence binding protein (ICSBP) is down- regulated in Bcr-Abl-induced murine chronic my- elogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol. 2000; 20:1149-1161.

150. Holtschke T, Lohler J, Kanno Y, et al. Immunodefi- ciency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-317.

151. Scheller M, Foerster J, Heyworth CM, et al. Al- tered development and cytokine responses of myeloid progenitors in the absence of transcrip- tion factor, interferon consensus sequence bind- ing protein. Blood. 1999;94:3764-3771.

152. Evan GI, Brown L, Whyte M, Harrington E. Apo- ptosis and the cell cycle. Curr Opin Cell Biol. 1995;7:825-834.

153. Santucci MA, Anklesaria P, Laneuville P, et al. Expression of p210 bcr/abl increases hematopoi- etic progenitor cell radiosensitivity. Int J Radiat Oncol Biol Phys. 1993;26:831-836.

154. Albrecht T, Schwab R, Henkes M, Peschel C, Hu- ber C, Aulitzky WE. Primary proliferating imma- ture myeloid cells from CML patients are not re- sistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol. 1996;95:501-507.

155. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR. Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem. 1995;270:22625-22631.

156. Selleri C, Maciejewski J, Pane F, et al. Fas-medi- ated modulation of Bcr/Abl in chronic myelog- enous leukemia results in differential effects on apoptosis. Blood. 1998;92:981-989.

157. Gora-Tybor J, Deininger M, Goldman JM, Melo JV. The susceptibility of Philadelpha chromo- some-positive cells to FAS-mediated apoptosis is

not linked to the tyrosine kinase activity of BCR- ABL. Br J Haematol. 1998;103:716-720.

158. Maguer Satta V, Burl S, Liu L, et al. BCR-ABL accelerates C2-ceramide-induced apoptosis. On- cogene. 1997;16:237-248.

Myeloid Leukemia Nursing Case Study